Accepted Manuscript Spicing up the treatment of mild to moderate ulcerative colitis Charles N. Bernstein, MD
PII: DOI: Reference:
S1542-3565(15)00378-X 10.1016/j.cgh.2015.04.003 YJCGH 54241
To appear in: Clinical Gastroenterology and Hepatology Accepted Date: 6 April 2015 Please cite this article as: Bernstein CN, Spicing up the treatment of mild to moderate ulcerative colitis, Clinical Gastroenterology and Hepatology (2015), doi: 10.1016/j.cgh.2015.04.003. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. All studies published in Clinical Gastroenterology and Hepatology are embargoed until 3PM ET of the day they are published as corrected proofs on-line. Studies cannot be publicized as accepted manuscripts or uncorrected proofs.
ACCEPTED MANUSCRIPT Bernstein CN
Charles N. Bernstein, MD University of Manitoba IBD Clinical and Research Centre Department of Internal Medicine, College of Medicine Faculty of Health Sciences, University of Manitoba Winnipeg, Manitoba, Canada
RI PT
Spicing up the treatment of mild to moderate ulcerative colitis
AC C
EP
TE D
M AN U
SC
Acknowledgements Dr. Bernstein is supported in part by the Bingham Chair in Gastroenterology. In the past two years he has been on advisory boards for Abbvie Canada, Shire Canada, Takeda Canada, Forrest Canada, Pfizer, Cubist Pharmaceutical and Theradiag. He has received a research grant from Abbvie Canada and education grants from Abbvie Canada, Shire Canada, Takeda Canada and Janssen Canada
Address correspondence to: Dr. Charles N Bernstein 804F-715 McDermot Avenue Winnipeg, MB, Canada R3E3P4 Telephone: 2047893369 E mail: [email protected]
1
ACCEPTED MANUSCRIPT Bernstein CN
While there has been a series of recent successful clinical trials in the treatment of moderate to severe ulcerative colitis (UC) using monoclonal antibodies (1-4), there has been little advancement in the management of mild to moderate UC. The most recent advancement in
RI PT
the treatment of mild to moderate UC has been oral budesonide multi-matrix system (MMX). In one study budesonide MMX 9 mg per day was shown to be more effective than placebo at
inducing clinical and endoscopic remission by 8 weeks in 17.4% compared with 4.5% in placebo
SC
treated participants (p
PII: DOI: Reference:
S1542-3565(15)00378-X 10.1016/j.cgh.2015.04.003 YJCGH 54241
To appear in: Clinical Gastroenterology and Hepatology Accepted Date: 6 April 2015 Please cite this article as: Bernstein CN, Spicing up the treatment of mild to moderate ulcerative colitis, Clinical Gastroenterology and Hepatology (2015), doi: 10.1016/j.cgh.2015.04.003. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. All studies published in Clinical Gastroenterology and Hepatology are embargoed until 3PM ET of the day they are published as corrected proofs on-line. Studies cannot be publicized as accepted manuscripts or uncorrected proofs.
ACCEPTED MANUSCRIPT Bernstein CN
Charles N. Bernstein, MD University of Manitoba IBD Clinical and Research Centre Department of Internal Medicine, College of Medicine Faculty of Health Sciences, University of Manitoba Winnipeg, Manitoba, Canada
RI PT
Spicing up the treatment of mild to moderate ulcerative colitis
AC C
EP
TE D
M AN U
SC
Acknowledgements Dr. Bernstein is supported in part by the Bingham Chair in Gastroenterology. In the past two years he has been on advisory boards for Abbvie Canada, Shire Canada, Takeda Canada, Forrest Canada, Pfizer, Cubist Pharmaceutical and Theradiag. He has received a research grant from Abbvie Canada and education grants from Abbvie Canada, Shire Canada, Takeda Canada and Janssen Canada
Address correspondence to: Dr. Charles N Bernstein 804F-715 McDermot Avenue Winnipeg, MB, Canada R3E3P4 Telephone: 2047893369 E mail: [email protected]
1
ACCEPTED MANUSCRIPT Bernstein CN
While there has been a series of recent successful clinical trials in the treatment of moderate to severe ulcerative colitis (UC) using monoclonal antibodies (1-4), there has been little advancement in the management of mild to moderate UC. The most recent advancement in
RI PT
the treatment of mild to moderate UC has been oral budesonide multi-matrix system (MMX). In one study budesonide MMX 9 mg per day was shown to be more effective than placebo at
inducing clinical and endoscopic remission by 8 weeks in 17.4% compared with 4.5% in placebo
SC
treated participants (p
